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Enormous progress has been made within
the past several decades in assessing human
cancer risk from chemical carcinogens. In
fact, attempts to estimate riskpotential have
given rise to contradictions between
Salmonella genotoxicity and rodent carcino-
genicity with the existence ofnongenotoxic
(Ames-negative) carcinogens and genotoxic
(Ames-positive) noncarcinogens (1-5). The
anomaly in question has provided us with a
clue to interpretation of the relationship
between genotoxicity and carcinogenicity.
In terms ofthe cause ofhuman carcinogen-
esis, the focus should now be placed on the
role of nonprogrammed cell proliferation
caused by exogenous agents rather than on
their genotoxicity (6-9).
Preston-Martin et al. (10) claimed that
human cancers are reflections of sustained
cell proliferation caused by cell proliferative
factors (consisting of chemical agents, hor-
mones, etc.) becau4e nondividing cells in
adults such as nerve cells and cardiomy-
ocytes never develop tumors. In addition,
Croy (11) assumed that estimation ofgeno-
toxic effects alone does not provide an accu-
rate assessment of cancer risk to humans
from chemical exposure. At present, when
newly developed chemicals give rise to
Ames-positive events, they are almost
always restricted from release into the
human environment by government regula-
tion. Ames-positive events however do not
always equate with carcinogenic events. It is
necessary therefore to detect carcinogenici-
ty by examining each chemical's ability to
stimulate cell proliferation.
More recently, Mason (12) and Okey
et al. (13) reported that some polycyclic
aromatic hydrocarbons, which are geno-
toxic carcinogens, have the capability to
increase cell proliferation through
dioxin-aromatic hydrocarbon (Ah) recep-
tor ligand complexes. Data also suggest
that cell proliferation increased by geno-
toxic carcinogens is closely related to the
development of tumors. This is the basis
for the studies presented in this paper,
which question to what extent noncarcino-
gens, as well as nongenotoxic and genotox-
ic hepatocarcinogens, exert cell prolifera-
tive action onhepatocytes in vivo (14-16).
The results show that most of the hepato-
carcinogens tested clearly accelerate hepa-
tocyte division whereas the majority of
noncarcinogens gave no such effect.
The data suggest that the capacity to
cause cell proliferation is common to
nongenotoxic and genotoxic carcinogens.
The mechanisms underlying this prolifera-
tion remain unclear in many cases, but the
role ofcell division in carcinogenesis is cer-
tainly a key point in the development of
tumors. This paper reviews issues regarding
nongenotoxic carcinogens and genotoxic
noncarcinogens and proposes an interpre-
tation in terms of nonprogrammed cell
proliferation.
Definition ofNongenotoxic
Carcinogens
The status of nongenotoxicants and geno-
toxicants should be evaluated using the
standard Ames test alone, including a liver
S9 mix from rats, mice, or hamsters. There
are two principal reasons for this: 1) the
standard Ames test has hitherto supplied a
large number ofthe screening data on exist-
ing noncarcinogens as well as carcinogens,
which provides the highest value of overall
concordance, compared to other established
genotoxicity tests (1); and 2) the simply
defined terminology facilitates a general
understanding to scientists studying muta-
tion, cancer, and other fields. According to
the definition ofnongenotoxic carcinogens,
at least 30% ofexisting carcinogens can be
assigned to this category (1-4).
Jackson et al. (17) reported that almost
all putative nongenotoxic carcinogens can
be shown to be genotoxic when tested with
a combination of several genotoxicity tests.
The combined test system, however, also
includes tests to detect tumor-promoting
agents that have cell proliferative capabili-
ties. Therefore, the data lead to questions
about whether nongenotoxic carcinogens
examined are indeed genotoxic.
In addition, almost all nongenotoxic
carcinogens are also believed to induce
genotoxicity in Salmonella TA102 (18),
which is supersensitive to active oxygen
production. Screening data obtained with
TA102 have, however, been limited so far.
Festing (19) indicated that F344 rats and
B6C3F1 mice are resistant to some genotox-
icants in U.S. National Toxicology
Program carcinogenesis bioassays and has
argued for the necessity of a multistrain
approach. Many scientists recognize that
Ames tests are too sensitive to DNA dam-
age to reliably estimate whether human and
rodent carcinogenicity will actually result
from long-term exposure.
Based on the definition ofnongenotoxic
carcinogens presented above, I believe that
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nongenotoxic carcinogens always result in
cell proliferation and that most latent and
modest DNA (equivocal) modifications
never lead to Ames-positive events. Further
details are presented below.
Cell Proliferation Caused by
Nongenotoxic Carcinogens and
Genotoxic Carcinogens
Most published reports have indicated that
induction of carcinogenesis by nongeno-
toxic carcinogens depends on the capability
to produce cell proliferation (20-31).
There is, however, no absolute consensus
because of the lack of adequate screening
data on the exact relation between
increased cell proliferation and nongeno-
toxic carcinogenicity (32). Therefore, I
conducted a comprehensive screening pro-
gram to examine whether nongenotoxic
hepatocarcinogens cause an increase in cell
proliferation after a single administration
of each chemical to male F344 rats (9
weeks ofage) or male B6C3F1 (8 weeks of
age) mice with the maximum tolerated
dose (MTD) and one-half the MTD
(14-16). After treatments at 24, 39, and
48 hr, hepatocytes were prepared by a col-
lagenase-perfusion technique and then
incubated for 4 hr in medium containing
370 kBq/ml of[methyl-3H]thymidine.
The results are summarized in Table 1.
In the replicative DNA synthesis (RDS)
test, 52 of63 nongenotoxic and genotoxic
hepatocarcinogens clearly induced
increased RDS events, whereas 24 of 31
genotoxic and nongenotoxic noncarcino-
gens did not cause such RDS increases.
One example, 2,3,7,8-tetrachlorodibenzo-
p-dioxin, was first reported as a hepatocyte
RDS-negative chemical (14); however, it
was subsequently found to give weak RDS-
positive results (M. Miyagawa and Y. Uno,
personal communications). The results
showed that almost all hepatocarcinogens
tested increased cell division, whether or
not they belonged to nongenotoxic or
genotoxic categories, indicating that the
potential to cause proliferation is common
to carcinogens regardless ofwhether they
have genotoxic potency, as suggested by
Cohen et al. (33).
The present RDS test has both
strengths and weaknesses for predicting
hepatocarcinogenicity of unknown chemi-
cals. The strength ofthe test is linked to its
short-term nature, and its weakness is the
high doses required in comparison to the
results of 2-year animal assays. Some sam-
ples showed false-positive or false-negative
RDS events relative to their established
hepatocarcinogenicity (Table 1). The false-
positive RDS events may be principally
caused by acute hepatotoxicity leading to
regenerative cell proliferation when acute
MTD levels are applied to animals. False-
negative results may occur because expo-
sure was performed by single gavage in the
experiments. With longer-term exposure,
such as in subacute and chronic toxicity
experiments, eventual induction of drug-
metabolizing enzymes appears to biotrans-
form highly toxic intermediates. This
would not be expected to occur with short-
term exposure. The second cause of false
negative results may be differences in drug
distribution resulting from the use ofa sin-
gle treatment versus the long-term expo-
sure in 2-year animal assays. Thus, the
RDS approach may not give a perfect
match for site, sex, or species in carcino-
genicity. Similar considerations are applica-
ble to any short-term experiments used to
predict chemical carcinogenicity at the
whole-body level. The present RDS data
reveal that the test is extremely useful for
early detection ofnongenotoxic hepatocar-
cinogens.
In considering the potential of chemi-
cals to stimulate cell proliferation, RDS
Table 1. Summary of hepatocyte replicative DNA synthesis (RDS)test results"
RDS incidence (%)
Rat Mouse Chemical
Ames-negativehepatocarcinogens
Aldrin
Acetaminophen
11-Aminoundecanoic acid
Barbital
Benzene
Benzofuran
Benzyl acetate
Carbontetrachloride
Chlordane
Chlorendic acid
Chlorobenzilate
Chlorodibromomethane
Chloroform
5-Chloro-o-toluidine
Clofibrate
p,p'-DDE
p,p'-DDT
Dehydroepiandrosterone
p-Dichlorobenzene
Dicofol
Dieldrin
Di(2-ethylhexyl)adipate
Di(2-ethylhexyl)phthalate
Diethylstilbestrol
p-Dioxane
Dipyrone
Ethenzamide
D,L-Ethionine
17a-Ethynylestradiol
Furfural
Heptachlor
Hexachlorobenzene
a-Hexachlorocyclohexane
Hexachloroethane
Hydroquinone
Methyl carbamate
4,4'-Methylenebis(N,NA-dimethyl)
benzenamine
N-Methylolacrylamide
Mirex
Pentachloroethane
Pentachlorophenol
Phenobarbital sodium
Phenylbutazone
Polybrominated biphenyls
Tannic acid
1,1,1,2-Tetrachloroethane
1,1,2,2-Tetrachloroethane
Tetrachloroethylene
9.4
14.9
RDS incidence(%)
Rat Mouse Chemical
Thioacetamide
1.09 Triadimefon
Trichloroacetic acid
1,1,2-Trichloroethane
0.96 2,4,6-Trichlorophenol
0.54 Tris(2-ethylhexyl)phosphate
1.41 Wy-14,643
1.48 Zearalenone
Ames-positivehepatocarcinogens
2.33 2,4-Diaminotoluene
1-13 Dimethyinitrosamine
1.13 2-Methoxv-5-methvIaniline
8.53 2,4,5-Trimethylaniline
10.2 Safrole
1.15 Trichloroethylene
2.3 Urethane
1.28 Ames-negatvenoncarcinogens 1.3 0.95 o-Anthlanilic acid 8.7 L-Ascorbic acid
1.87 Benzoin
Benzyl alcohol 0578 Butylatedhydroxyltoluene
2 .60 e-Caprolactam 2.6 1.60 3-Chloro-p-toluidine 7.9 o-Dichlorobenzene 1.4
2,4-Dichlorophenol
EDTAtrisodium
Geranyl acetate
Lindane
9.5 Lithocholic acid 1.43 D-Mannitol 1.84 D,L-Menthol
0.66 Methoxychlor
1.21 Phenol 1041 Piperonyl butoxide 1.04 Sulfisoxazole
1.1 Titanium dioxide
Toluene
0.73 -LTryptophan
1.04 Ames-positivenoncarcinogens
2.78 2-Chloroethanol
1.01 2,5-Diaminotoluene H2S04
2.0 2.78 2,6-Diaminotoluene
Dimethoate
4.5 8-Hydroxyquinoline
12.7 Methylmethacrylate
0.88 4-Nitroanthranilic acid
I.-
1.41
0.60
4-Nitro-o-phenylenediamine
p-Phenylenediamine 2HCI
1 3.8
0.88
0.98
1.28
4.1
2.3
10.8
6.0
2.5
5.5
1.4
13.2
1.36
9.6 _
9.2 0.80
3.0 0.89
5.7 0.88
- 2.05
6.0 1.69
- 0.85
"Incidences of 0.4% or more are judged as positive responses in the mouse RDS test, those of 1.0% or
more are positive inthe ratRDStest; -indicates negative response.
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events can be classified into three categories:
1) binding to the steroid-thyroid-retinoic
acid receptor, a type which is not related to
liver injury, 2) growth factor-binding due to
chemical injury to the liver or other organs,
and 3) a result of tumor promoters that
never cause equivocal DNAmodifications.
The chemical-binding steroid receptor
superfamily is known to include the steroid
hormonelike receptor, the peroxisome pro-
liferator-activated receptor (PPAR), and
probably the Ah receptor (34-37. Each
receptor might act as a ligand for some of
the RDS-positive carcinogens listed in
Table 1: a steroid hormonelike receptor for
dehydroepiandrosterone and 17a-
ethynylestradiol; the PPAR for dehy-
droepiandrosterone, clofibrate, di(2-ethyl-
hexyl)adipate (DEHA), di(2-ethylhexyl)-
phthalate (DEHP), phenobarbital sodium,
tetrachloroethylene, trichloroethylene, and
Wy-14,643; and the Ah receptor for
benzo[a]pyrene, p,p'-DDT, p,p'-DDE,
and polybrominated biphenyls (34,36,37).
Although there is no clear evidence for
an increase in cell proliferation through the
PPAR receptor (37), some proto-oncogenes
promoting cell proliferation, e.g., fos and
jun, are known to be activated (34,38,39).
Our RDS data suggest that formation of
PPAR-ligand complexes also leads to cell
proliferation (Table 1). Thus, steroid-
superfamily receptor-mediated cell prolifer-
ation can be considered to be principally
involved in early development of hepato-
cyte RDS induction. In addition, ligands
may simultaneously give rise to equivocal
DNA modifications. Progression of both
phenomena in the same cells may result in
effective disruption ofcell-cycle controls so
that hepatocarcinomas eventually arise.
Among these receptors, particular attention
is now being paid to the Ah receptor
because it can react with a wide range of
nongenotoxic and genotoxic agents as a li-
gand and it principally regulates induction
of CYPlAI to metabolically activate poly-
cyclic aromatic hydrocarbons (13).
Several growth factors are also known
to increase cell proliferative events in spe-
cific cells in tissues (40), but the relation-
ship between the roles of growth factors
and cell proliferation in carcinogenesis is
extremely difficult to assess. With regard to
hepatocyte cell proliferation, the action of
hepatocyte growth factor (HGF) investigat-
ed by Nakamura and his co-workers
(41,42) must be considered: HGF secreted
from liver and other organs in response to
chemical injury is known to promote the
division of hepatic parenchymal cells by
means ofparacrine/endocrine mechanisms;
moreover, the nature of the HGF-binding
receptor has also been identified as a met
proto-oncogene product (43). Other
growth factors taken into the liver are epi-
dermal growth factor and transforming
growth factor-fl1. At present, there is no
simple explanation of how growth factors
act in combination to bring about compli-
cated events in vivo.
Of several RDS-positive carcinogens
listed in Table 1, at least 13 samples are
generally well known to be hepatotoxicants
in rats and mice (13,14): aldrin, benzene,
carbon tetrachloride, chloroform, penta-
chloroethane, pentachlorophenol, tannic
acid, 1,1,1,2-tetrachloroethane, terachloro-
ethylene, thioacetamide, trichloroacetic
acid, trichloroethylene, and 1,1,2-
trichloroethane. Thus, damage-induced
HGF is likely to play an important role in
hepatocyte RDS induction. In addition, the
ligand may give rise simultaneously to
equivocal DNA modifications, as in the
case of the steroid-superfamily receptor.
Interestingly, hepatocyte RDS events do
not always directly reflect hepatotoxicity,
either pathologically or biochemically (e.g.,
when HGF is secreted through paracrine
mechanisms). Therefore, increased hepato-
cyte RDS events might not be due to sim-
ple hepatotoxicity to target population.
In vivo liver-tumor promoters such as
butylated hydroxytoluene and lithocholic
acid, which are classified as noncarcino-
gens, might cause increased hepatocyte
RDS events by some mechanisms (Table
1). Such agents principally act through
protein kinase C to stimulate cell division
(44). Details of the combination of differ-
ent parameters involved in hepatocyte RDS
induction by particular agents require fur-
ther attention.
Examination of early RDS inductive
events provides us with a reliable and sim-
ple test to determine whether unknown
chemicals possess proliferative stimulus
potential. The data obtained so far indicate
that RDS-positive andAmes-positive agents
are hepatocarcinogens in humans and
rodents except for 4-nitro-o-phenylenedi-
amine and RDS-positive and Ames-nega-
tive agents, which are possible hepatocar-
cinogens. The data show that RDS-negative
and Ames-negative agents are probably
noncarcinogens in the liver. Thus, use of
the two tests in combination is an effective
approach for classification purposes.
What is the significance ofearlyhepato-
cyte RDS induction for hepatocarcinogene-
sis? The process may lead to cell death for
almost all RDS-inductive hepatocytes by
means of apoptosis, which involves one of
the normal functions ofthe p53 tumor-sup-
pressor gene (45). There are four points to
support this: 1) experimental data show
that the maximum peak of early RDS is
observed approximately 24 to 48 hr after
chemical treatments and it disappears soon
afterwards (14,15,23); 2) it is generally con-
sidered that normal p53 function is main-
tained within 48 hr under conditions of
RDS induction; 3) it appears that unequiv-
ocal DNA modifications formed by geno-
toxic hepatocarcinogens greatly contribute
to apoptosis (45); and 4) there is no direct
correlation between hepatocyte RDS inci-
dence and the hepatocarcinogenic potency
so that the affected hepatocytes are unlikely
to be precursor cell candidates for subse-
quent hepatic adenomas and carcinomas.
The measured RDS event after a single
exposure may simply reflect the early in
vivo response to chemical exposure, which
is likely to be immediately followed by
homeostasis. In 2-year animal bioassays,
however, it is likely that such cell division
occurs continuously and repeatedly at low
levels in target issues. As a result, affected
cells, apoptosis-resistant cells, will be
expected to persist and play a role in the
generation of malignant tumor cells over
long application times.
Differences between Nongenotoxic
Carcinogens andTumor Promoters
Development oftumors is likely to require
at least two initial steps: equivocal DNA
modifications and nonprogrammed cell
division. The mechanisms underlying car-
cinogenesis are widely understood to
involve multistage, initiation, promotion,
and progression processes. Experiments
using two-stage animal models have sup-
ported the terminology "tumor-initiating"
and "tumor-promoting" agents, leading to
confusion. Pure tumor promoters have
been characterized as not only incomplete
carcinogens but also as nongenotoxicants.
Hildebrand et al. (46) and Perera (47)
have indicated that the term "tumor pro-
moters" should be limited to the discussion
oftwo-stage model systems in which tumor
development is examined after the applica-
tion of an initiating agent. The term
"nongenotoxic carcinogen" should be used
to designate an Ames-negative agent that is
capable of causing the development of
malignant tumors in 2-year bioassays when
animals are exposed to that agent alone.
Definite differences between nongenotoxic
carcinogens and tumor promoters are not
likely to be established; therefore, confu-
sion in the application ofterminology will
remain.
Tumor promoters are often considered
to be carcinogenic when they test positive
in 2-year animal bioassays, which leads to
the interpretation that tumor promoters
are equal to nongenotoxic carcinogens.
These nongenotoxic carcinogens are some-
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times defined in terms oftheir carcinogenic
potency in a range of animal species,
strains, sexes, tissues, or organs, in contrast
to the more limited promoter case.
Experimental data for nongenotoxic car-
cinogens tend to show that the two groups
are equivalent in practice, and tumor pro-
moters may cause cell proliferation that is
tissue or organ specific in animals (48). A
representative nongenotoxic carcinogen,
benzene, which is a rodent carcinogen as
well as a human carcinogen, induces
tumors in a wide range of animal species
and strains in both sexes and in many tis-
sues and organs (4). It is questionable,
therefore, whether all nongenotoxic car-
cinogens are simply tumor promoters.
The confusion in use of the terms
"nongenotoxic" and "tumor promoters"
principally occurs when the cause ofhuman
cancers is considered. Current understand-
ing suggests that the capacity of chemicals
to cause cell proliferation is more important
than the initiating effects of the chemicals.
As far as the occurrence ofhuman cancers is
concerned, it may not be necessary to make
a strict distinction between nongenotoxic
carcinogens and tumor promoters as
responsible agents. In the experimental
field, however, a strict discrimination is
always needed for regulatory authorities to
properly assess human cancer risk.
My hypothesis is that hepatocarcino-
genicity is due to stimulation ofcell prolif-
eration and production ofequivocal DNA
modifications. While the ability of chemi-
cals to induce hepatocyte proliferative divi-
sion can be determined in RDS experi-
ments, equivocal DNA modifications are
difficult to estimate. Overcoming this
problem would be of great assistance in
assessing human cancer risk. After exami-
nation of in vitrolin vivo DNA-binding
adducts caused by more than 200 different
DNA-binding agents, Hemminki (49)
reported on the relationship between ulti-
mate DNA adducts and malignant tumor
development. A clear understanding awaits
comprehensive in vivo DNA-binding data
and sufficient quantitative results with
regard to dose dependency ofresponse.
For example, DNA adducts have not
yet been demonstrated for the representa-
tive human carcinogen benzene. The
microsomal oxidation ofbenzene to phenol
and of phenol to catechol and hydro-
quinone are known to be major pathways
in the metabolism of benzene. The nature
of the ultimate carcinogenic metabolite
however has not been resolved, although
benzene oxide, catechol, hydroquinone,
and benzoquinone have each been pro-
posed as important contributors to its car-
cinogenicity (50). Ofthe benzene metabo-
lites reported by Leanderson and Tagesson
(51), catechol and hydroquinone are
known to form 8-hydroxydeoxyguanosine
in vitro (52). Thus, determination ofequiv-
ocal DNA modifications requires further
investigation because it is extremely impor-
tant for distinguishing so-called nongeno-
toxic carcinogens from tumor promoters.
In the interpretation of increased RDS
events, a key point is whether it is possible
to distinguish nongenotoxic carcinogens
from tumor promoters. The difference is
based on whether the chemical possesses the
ability to cause equivocal DNA modifica-
tions (e.g., oxidative DNA adducts). With
regard to cell proliferation induced by
tumor promoters, we can speculate that
inductive RDS events involve the cascade-
pathway protein kinase C (44) without
equivocal DNA modifications, and such cell
proliferative conditions might themselves
never lead to tumorigenesis. Nongenotoxic
carcinogens, on the other hand, that pro-
duce equivocal DNA modifications (e.g.,
oxidative DNA adducts) were exemplified
by 8-hydroxydeoxyguanosine (52). Such
DNA adducts are considered to never cause
genotoxic events in the standard Ames test,
but they might contribute to disruption of
normal cell division, although any causative
significance for oxidative DNA adducts in
cell proliferation remains to be proven.
Data on formation of oxidative DNA
adducts have been obtained for several car-
cinogens in both in vivo and in vitro exper-
iments (53). With hepatocarcinogens and
experimental animal exposure in vivo, at
least four agents, [DEHA and DEHP (54),
2-nitropropane (55), and polychlorinated
biphenyls (56)] have been shown to cause
8-hydroxydeoxyguanosine in hepatocyte
DNA in rats; of these agents, DEHP and
DEHA also increased hepatocyte RDS
events (Table 1). Thus, oxidative DNA
stress might lead to development of hepa-
tocarcinogenesis in cooperation with cell
proliferation.
Some ofthe nongenotoxic noncarcino-
gens examined also induced hepatocyte
RDS events (Table 1). Such false-positive
RDS events might be due to a tumor-pro-
moting action on hepatocytes in vivo. As
indicated by Ledda-Columbano et al. (39),
differences between nongenotoxic hepato-
carcinogen-induced and tumor promoter-
induced or mitogen-induced cell prolifera-
tion might be distinguished by analyzing
the nature ofoverexpression ofproto-onco-
genes during early hepatocyte RDS induc-
tion. This approach might similarly be
important to distinguish nongenotoxic car-
cinogens from tumor promoters.
. A representative promoter without car-
cinogenic potency, 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) was found to be
carcinogenic in a long-term study when it
was repeatedly applied to the skin of
BALB/c mice (57). Proliferation of ker-
atinocytes is known to be controlled by
TGF-R1 (40), and hepatocytes respond to
HGF (41,42). In addition, keratinocytes in
the normal skin ofadults are always present
as immature, intermediate, and mature
cells; hepatocytes in the normal liver of
adults are a homogeneous population of
mature, differentiated cells. In considering
these backgrounds, cell-cycle control mech-
anisms ofkeratinocytes probably differ from
those ofhepatocytes. Namely, skin carcino-
genesis byTPA might be due to chronic cell
proliferation involving immature ker-
atinocytes that may be more susceptible to
cell-cycle checkpoint disruption than mature
cells, leading to genetic instability and there-
fore skin carcinogenesis.
The hypothesis that tumor promoters
cause cell proliferation without equivocal
DNA modifications may therefore be limit-
ed to mature cell cases (e.g., hepatocytes
and renal tubule cells). This is ofinterest in
view ofthe finding that almost all existing
nongenotoxic carcinogens induce malignant
tumors in the liver and kidney (1,4,5).
Genotoxic Noncarcinogens
Genotoxicity tests have been principally per-
formed with bacteria (the Ames test), mam-
malian cell lines (in vitro chromosome aber-
ration test), and hematopoietic cells (in vivo
mouse micronucleus test). The existence of
genotoxic noncarcinogens is considered to
be a reflection of the properties of the bio-
logical indicator cells used in established
genotoxicity tests. Each biological indicator
cell is independently capable of progressing
through the cell cycle and dividing, but this
is not necessarily the case for cells in tissues,
such as hepatocytes and renal tubular
epithelial cells. This is probably due to the
functions ofgapjunctions (58-60).
The cells used in genotoxicity tests are
far more susceptible to conversion ofgeno-
toxic events to fixed mutations than cells
existing in tissues. The applied systems
have a number of defects in other areas,
e.g., overapplication of drug-metabolizing
enzymes, overdoses, and a relative lack ofa
detoxication process in vitro. Application of
new genotoxicity tests that use mammalian
cells with functioning gap junctions and a
normal complement of enzymes is thus
needed to prevent false-positive data for
genotoxic noncarcinogens in the future.
In this respect, Cunningham et al. (27)
reported that, although 2,4- and 2,6-
diaminotoluene analogs were equally geno-
toxic for the Ames test, only 2,4-diamino-
toluene was hepatocarcinogenic and
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increased hepatocyte RDS induction
(Table 1). Therefore, they argued that
induction of liver tumors is likely to
require both genotoxic action and stimula-
tive potential for cell proliferation.
In addition, Goldsworthy et al. (8)
reported interesting data on hepatocyte lacl
genotoxic events and hepatocyte prolifera-
tion in transgenic mice using two alkylating
agents, N-dimethylnitrosamine as a repre-
sentative hepatocarcinogen and methyl-
methane sulfonate as a nonhepatocarcino-
gen. Both chemicals are known to be posi-
tive in in vivo mouse hepatocyte unsched-
uled DNA synthesis tests (61) as well as in
the three types of genotoxicity tests. The
data showed that N-dimethylnitrosamine
caused laclgenotoxic events and hepatocyte
proliferation in hepatocytes in vivo, whereas
methylmethane sulfonate induced neither.
These findings also provide us with evi-
dence that hepatocytes in tissue in vivo
need cell proliferation for genotoxic lesions
to become fixed and carcinogenesis to
result. Thus, determination ofproliferative
response is considered to be most appropri-
ate to predict hepatocarcinogenicity.
Relationship between Cell
Proliferation and Chemical
Hepatocarcinogenesis
Nongenotoxic carcinogens and tumor pro-
moters can also act to clonally expand
spontaneously occurring, initiated cells.
Although clonal expansion by both types of
agents may be generally accepted as con-
tributory to development oftumors, at pre-
sent it is unlikely to be accepted as a theory
of tumor development for the reasons
described below.
Ward et al. (62) reasoned that, if the
rate of spontaneously occurring, initiated
cells is similar for each specific tissue, then
more spontaneous cancers should occur in
larger organs. Liu et al. (63) reported that
HGF inhibited proliferation in glutathione
S-transferase placental form-positive rat
hepatocytes (putative preneoplastic foci
cells) induced by N-diethylnitrosamine,
whereas it stimulated cell division in nonle-
sion areas. Moreover, Schulte-Hermann et
al. (64) claimed that putative preneoplastic
foci cells ofrat livers exhibit approximately
10-fold higher rates ofapoptosis than nor-
mal hepatocytes. These points must be
taken into account in any explanation
based on clonal expansion. With regard to
carcinogenesis by genotoxic and nongeno-
toxic carcinogens, the theory of genetic
instability, which involves disruption of
growth arrest checkpoints, is now consid-
ered to be of great advantage to under-
standing mechanisms ofaction.
The following summaryofhow cell pro-
liferation might act in carcinogenesis takes
into account recent information. First ofall,
an imbalance of the deoxynucleotide pool
occurs (65,66), stimulating dihydrofolate
and DNApolymerase a, for example. In the
first stage of cell proliferation, this imbal-
ance might be triggered by some factors,
such as steroid-superfamily receptor-ligand
complexes or HGF-receptor- ligand com-
plexes, as described above. Ofthese factors,
some are known to contribute to overexpres-
sion of some proto-oncogenes, which leads
to further progression of nonprogrammed
cell proliferation (34-36).
In the second stage, appreciation ofthe
role of sustained cell proliferation in the
carcinogenesis procegs requires a compre-
hensive understanding with regard to
methylation status (67-69). Namely, a
chronically maintained high rate of cell
division can give rise to an imbalance in
normal DNA methylation levels involving
5-methylcytosine (67-70), leading to
hypermethylation or hypomethylation of
intracellular DNA. Alteration of DNA
methylation levels may directly cause genet-
ic instability that can result in spontaneous
DNA changes (C to T transitions), which
are a type ofequivocal DNA modifications.
In the third stage, when genes responsi-
ble for controlling normal DNA replication
such as p53 (71) become inactivated, non-
programmed cell division can progress
without G1 arrest involving the repair of
DNA alteration (68-70,72-75). Thus, dis-
ruption of cell-cycle control check points
increases nonprogrammed cell proliferation
with elevated genetic instability, leading to
the possibility of malignant tumor cells
arising in the future. Namely, in genetic
instability theory, an abnormality of p53
functions is considered a key factor in
resolving the relationship between cell pro-
liferation and chemical carcinogenesis.
A number ofrecent studies have provid-
ed detailed understanding ofthe complexity
of cell-cycle control mechanisms. With
regard to the initiation ofprogrammed cell
proliferation that Taya (76) reviewed, the
normal RB tumor-suppressor gene plays an
extremely important role (77). When pRB
is phosphorylated at the G1/S border with
active cyclin-dependent kinase (Cdk)-G1
cyclin complexes, its linked transcription
factor (E2F) (78) is released, which activates
genes relating to progression ofcell prolifer-
ation. Thus, phosphorylation involving
Cdk-G1 cyclin complexes is promoted by
the products of proto-oncogenes (myc, ras,
etc.) and is inhibited by products oftumor-
suppressor genes (p15, p16, p27, etc.), thus
controlling normal cell division by means of
the actions of "brakes and accelerators." It
has been argued that the mechanisms of
normal cell division are disrupted in carci-
noma cells (76).
With regard to inductive RDS events,
namely nonprogrammed cell proliferation
induced by chemicals, I have proposed that
the initiation step requires biological stim-
uli that may give rise to an imbalance in
the normal DNAmethylation status. There
are a number ofways in which this might
also trigger unscheduled RDS. Taya (76)
claimed that cell division is also accelerated
when tumor-suppressor gene products
(e.g., p15, p16, p27) are directly inactivat-
ed by exogenous chemicals. The DNA
methylation status is affected by any imbal-
ance between DNA methyltransferase and
its demethylase activities in target cells
(69). It needs to be clarified whether geno-
toxic or nongenotoxic carcinogens might
induce elevated activity of either DNA
methyltransferase or its demethylase. DNA
methylation processes are known to require
choline and methionine; by administering
a diet deficient in both chemicals, hepato-
carcinomas can be induced, indicating a
role for hypomethylation of hepatocyte
DNA (79). An imbalance in the DNA
methylation status may thus exert effects
without the necessity ofsustained cell pro-
liferation.
Finally, hepatocarcinogenesis should be
considered from the standpoint of two
events that occur with the lesion progres-
sion process and increasing age in experi-
mental animals. In 2-year animal bioassays,
it appears that progressively more malig-
nant clones are repeatedly created from
background altered populations. Also, with
increasing age, the normal function of
tumor-suppressor genes tends to gradually
and spontaneously disrupt various cell
types. By means of both continuous
processes, apoptosis-resistant, semi-abnor-
mal hepatocytes, which can go through the
first gate of the pathway to tumors with
accumulated genetic instability, may be
selected. Such genetic instability will con-
tribute to stepwise disruption ofoncogenes
and some tumor-suppressor genes. When
tumor-suppressor genes lose their normal
function, apoptosis-resistant abnormal
hepatocytes may be able to go through the
next gates leading to malignancy. This
hypothesis is based on the occurrence of
apoptosis-resistant abnormal hepatocytes
and is supported by the data of Roberts et
al. (80), who reported that the majority of
the hepatocytes generated during chemical-
induced hyperplasia were protected from
apoptosis during liver regression. In con-
clusion, risk assessment ofchemical agents
should focus on control ofearly cell prolif-
eration in vivo-, this present short-term test
is available for this purpose.
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